# US 10,370,447 B2 · Molecules with specificity for CD79 and CD22

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,447 B2
- Document ID: US10370447B2
- Status: Granted
- Kind: B2
- Application number: 15/326,501
- Filed: 2015-07-16
- Published: 2017-07-20
- Granted: 2019-08-06
- Earliest claimed: 2014-07-16
- Assignees: Ucb Biopharma Sprl
- Applicants: Ucb Biopharma Sprl
- Inventors: Helene Margaret Finney; Stephen Edward Rapecki; Michael John Wright; Kerry Louise Tyson
- Web page: https://patentgrep.com/patent/US10370447B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/624: Disulfide-stabilized antibody (dsFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.

## Claims

### Claim 1

A multispecific molecule comprising a binding domain specific to human antigen CD22 and a binding domain specific to human antigen CD79b,
wherein the binding domain specific to human antigen CD22 comprises 3 heavy chain CDRs comprising SEQ ID NO: 128 for CDRH1, SEQ ID NO: 129 for CDRH2 and SEQ ID NO: 130 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 125 for CDRL1, SEQ ID NO: 126 for CDRL2 and SEQ ID NO: 127 for CDRL3; or
comprises 3 heavy chain CDRs comprising SEQ ID NO: 138 for CDRH1, SEQ ID NO: 139 wherein the Cys has been replaced by Ser for CDRH2 and SEQ ID NO: 140 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 135 for CDRL1, SEQ ID NO: 136 for CDRL2 and SEQ ID NO: 137 for CDRL3; and
wherein the binding domain specific to human CD79b comprises 3 heavy chain CDRs comprising specific for CD79b and comprises 3 heavy chain CDRs comprising SEQ ID NO: 78 for CDRH1, SEQ ID NO: 79 for CDRH2 and SEQ ID NO: 80 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 75 for CDRL1, SEQ ID NO: 76 for CDRL2 and SEQ ID NO: 77 for CDRL3; or
3 heavy chain CDRs comprising SEQ ID NO: 78 for CDRH1, SEQ ID NO: 79 for CDRH2 and SEQ ID NO: 80 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87 for CDRL3; or
3 heavy chain CDRs comprising SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87 for CDRL3; or
3 heavy chain CDRs comprising SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 75 for CDRL1, SEQ ID NO: 76 for CDRL2 and SEQ ID NO: 77 for CDRL3.

### Claim 2 (depends on 1)

The multispecific molecule according to claim 1, wherein the molecule is bispecific.

### Claim 3 (depends on 1)

The multispecific molecule according to claim 1, wherein the molecule is a fusion protein.

### Claim 4 (depends on 1)

The multispecific molecule according to claim 1, wherein the molecule format is selected from diabody, scdiabody, triabody, tandem scFv, FabFv, Fab′Fv, FabdsFv, Fab-scFv, Fab-dsscFv, Fab-(dsscFv)2, diFab, diFab′, tribody, tandem scFv-Fc, scFv-Fc-scFv, scdiabody-Fc, scdiabody-CH3, Ig-scFv, scFv-Ig, V-Ig, Ig-V, Duobody and DVD-Ig.

### Claim 5 (depends on 1)

The multispecific molecule according to claim 1, wherein each binding domain is monospecific.

### Claim 6 (depends on 1)

The multispecific molecule according to claim 1, wherein the multispecific molecule comprises no more than one binding domain which is specific to CD22 and no more than one binding domain which is specific to CD79b.

### Claim 7 (depends on 1)

The multispecific molecule according to claim 1, wherein the binding domain which is specific to CD22 and the binding domain which is specific to CD79a andler CD79b are independently selected from a Fab, scFv, Fv, dsFv and dsscFv.

### Claim 8 (depends on 1)

The multispecific molecule according to claim 1, in which the binding domains are humanised.

### Claim 9 (depends on 1)

The multispecific molecule according to claim 1, which further comprises a binding domain specific to serum albumin.

### Claim 10 (depends on 1)

A composition comprising one or more multispecific molecules as defined in claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 11

A multispecific molecule comprising a binding domain specific to human antigen CD22 and a binding domain specific to human antigen CD79b, wherein the binding domain specific to human antigen CD22 comprises 3 heavy chain CDRs comprising SEQ ID NO: 138 for CDRH1, SEQ ID NO: 139, wherein Cys has been replaced by Ser for CDRH2 and SEQ ID NO: 140 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 135 for CDRL1, SEQ ID NO: 136 for CDRL2and SEQ ID NO: 137 for CDRL3; and
wherein the binding domain specific to human CD79b comprises 3 heavy chain CDRs comprising SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87 for CDRL3.